Taisho Pharmaceutical Holdings Co., Ltd.

TSE:4581 Stock Report

Market Cap: JP¥703.3b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Taisho Pharmaceutical Holdings Past Earnings Performance

Past criteria checks 0/6

Taisho Pharmaceutical Holdings's earnings have been declining at an average annual rate of -25.1%, while the Pharmaceuticals industry saw earnings growing at 3.1% annually. Revenues have been growing at an average rate of 2.9% per year. Taisho Pharmaceutical Holdings's return on equity is 1.3%, and it has net margins of 2.6%.

Key information

-25.1%

Earnings growth rate

-25.9%

EPS growth rate

Pharmaceuticals Industry Growth3.4%
Revenue growth rate2.9%
Return on equity1.3%
Net Margin2.6%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Taisho Pharmaceutical Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TSE:4581 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23320,3858,421143,52620,727
30 Sep 23319,96015,570138,81220,727
30 Jun 23313,11417,609136,76020,727
31 Mar 23301,38118,997134,10420,727
31 Dec 22295,82125,047131,88619,366
30 Sep 22282,56021,091131,63819,366
30 Jun 22273,38817,694133,20919,366
31 Mar 22268,20313,122133,72219,366
31 Dec 21267,7318,055135,03620,251
30 Sep 21266,2414,930134,70120,251
30 Jun 21270,8418,431134,99520,251
31 Mar 21281,98013,316135,77020,251
31 Dec 20291,48916,837135,08222,876
30 Sep 20302,21916,846140,06622,876
30 Jun 20303,29015,589140,90422,876
31 Mar 20288,52720,531136,04722,876
31 Dec 19272,99315,124132,21720,801
30 Sep 19264,26821,138123,10020,801
30 Jun 19260,06345,910118,74220,801
31 Mar 19261,55148,593118,15020,801
31 Dec 18264,19056,614115,41721,150
30 Sep 18270,95362,097118,78721,150
30 Jun 18273,30839,834119,88821,150
31 Mar 18280,09231,679124,85721,150
31 Dec 17279,14031,574125,33921,260
30 Sep 17277,39627,298125,70221,260
30 Jun 17278,87427,370127,05621,260
31 Mar 17279,77328,781125,00021,260
31 Dec 16281,58827,438124,30621,768
30 Sep 16285,15824,691124,66521,768
30 Jun 16290,35424,732124,24021,768
31 Mar 16290,13522,473126,16721,768
31 Dec 15293,71723,594126,16621,554
30 Sep 15294,67723,217127,42221,554
30 Jun 15291,33922,556148,8090
31 Mar 15290,49824,529124,72021,554
31 Dec 14289,77724,493126,87621,874
30 Sep 14293,19928,769124,44321,874
30 Jun 14296,15031,940122,24621,874
31 Mar 14295,95832,693121,13521,875
31 Dec 13292,83832,311117,99823,331
30 Sep 13289,77930,170118,79723,331
30 Jun 13285,57326,139118,37223,331

Quality Earnings: 4581 has a large one-off loss of ¥7.9B impacting its last 12 months of financial results to 31st December, 2023.

Growing Profit Margin: 4581's current net profit margins (2.6%) are lower than last year (8.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 4581's earnings have declined by 25.1% per year over the past 5 years.

Accelerating Growth: 4581's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 4581 had negative earnings growth (-66.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-4.1%).

Return on Equity

High ROE: 4581's Return on Equity (1.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/04/12 20:24
End of Day Share Price 2024/04/11 00:00
Earnings2023/12/31
Annual Earnings2023/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Taisho Pharmaceutical Holdings Co., Ltd. is covered by 16 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Ritsuo WatanabeBofA Global Research
Hidemaru YamaguchiCitigroup Global Markets Japan Inc.